Repligen Corp (NASDAQ: RGEN) has reported E.P.S. of $0.04 for its first fiscal quarter (ending March 31) versus $0.52 for the same period a year ago — a decline of -92%. This result fell short of the consensus estimate of $0.45 by $-0.41. For the latest four quarters through March 31, E.P.S. were $0.27 versus $3.03 for the same period a year ago — a decline of -91%.
Recent Price Action
On 5/1/24, Repligen Corp (NASDAQ: RGEN) stock declined by -3.6%, closing at $158.36. Moreover, unusually high trading volume at 197% of normal accompanied the decline. The stock has been strong relative to the market over the last nine months but has declined -7.5% during the last week.
Current PriceTarget Research Rating
RGEN is expected to continue to be a modest Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Repligen has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Repligen has a very low Appreciation Score of 15 but a slightly positive Power Rating of 62, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment